RT Book, Section
A1 Yadav, Hemang
A1 Peters, Steve G.
A1 Kotloff, Robert M.
A2 Grippi, Michael A.
A2 Antin-Ozerkis, Danielle E.
A2 Dela Cruz, Charles S.
A2 Kotloff, Robert M.
A2 Kotton, Camille Nelson
A2 Pack, Allan I.
SR Print(0)
ID 1207692935
T1 Noninfectious Pulmonary Complications of Hematopoietic Stem Cell and Solid Organ Transplantation
T2 Fishman’s Pulmonary Diseases and Disorders, 6e
YR 2023
FD 2023
PB McGraw-Hill Education
PP New York, NY
SN 9781260473988
LK accessmedicine.mhmedical.com/content.aspx?aid=1207692935
RD 2025/03/18
AB Hematopoietic  stem-cell  transplantation  (HSCT)  is  a  potentially  curative  treatment  option  for  hematologic  and  lymphoid  cancers,  selected  solid  tumors,  and  nonneoplastic  diseases,  including  autoimmune  disorders,  amyloidosis,  and  aplastic  anemia.1  Since  the  first  HSCT  was  performed  in  1956,  there  has  been  a  steady  increase  in  the  number  performed  worldwide,  with  more  than  35,000  autologous  and  30,000  allogeneic  HSCTs  now  performed  annually.2  In  the  United  States  in  2018,  a  total  of  9028  allogeneic  and  14,006  autologous  HSCTs  were  performed.3  As  peritransplant  management  strategies  have  improved,  HSCTs  are  being  performed  increasingly  often  for  a  wider  range  of  conditions,  and  in  patients  who  are  older  and  with  more  comorbidities.